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Transcranial direct current stimulation (tDCS) has attracted significant attention from
patients and clinicians for its potential to elicit therapeutic benefit in a number of neu-
rological and psychiatric conditions, and to facilitate rehabilitation after neurological
injury.1 Tested indications include recovery of speech andmotor loss following stroke,2
mitigation of various forms of chronic pain,3 and reduction in signs and symptoms
of particular types of depressive and anxiety disorders4 (for overview, see Kuo et al.,
20145). The mechanisms of transcranial electrical stimulation have been systemati-
cally characterized over decades, while themost rigorous clinical trials have considered
1 Min-Fang Kuo,Walter Paulus &Michael A. Nitsche,Therapeutic Effects of Non-Invasive Brain Stimulation with
Direct Currents (tDCS) in Neuropsychiatric Diseases, 85 Pt 3 NEUROIMAGE 948–60 (2014); Andre´ R. Brunoni
et al., Transcranial Direct Current Stimulation for Acute Major Depressive Episodes: Meta-Analysis of Individual
Patient Data, 208 BR. J. PSYCHIATRY J. MENT. SCI. 522–31 (2016); Andre Russowsky Brunoni et al., Clinical
Research with Transcranial Direct Current Stimulation (tDCS): Challenges and Future Directions, 5 BRAIN STIM-
ULAT. 175–95 (2012).
2 JodieMarquez et al.,TranscranialDirect Current Stimulation (tDCS):Does it haveMerit in StrokeRehabilitation?
A Systematic Review, 10 INT. J. STROKE 306–16 (2015).
3 TimothyY.Mariano et al.,TranscranialDirect Current Stimulation (tDCS)Targeting LeftDorsolateral Prefrontal
CortexModulates Task-Induced Acute Pain inHealthy Volunteers, 17 PAINMED.MALDENMASS. 737–45 (2016).
4 AndreR.Brunoni et al.,TheSertraline vs. ElectricalCurrentTherapy forTreatingDepressionClinical Study:Results
fromaFactorial, Randomized, ControlledTrial, 70 JAMAPSYCHIATRY 383–91 (2013); Brunoni et al., supranote
1; Colleen K. Loo et al., Transcranial Direct Current Stimulation for Depression: 3-Week, Randomised, Sham-
Controlled Trial, 200 BR. J. PSYCHIATRY 52–59 (2012).
5 Kuo, Paulus &Nitsche, supra note 1.
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contexts of use, conditions of test subjects, and ecological variables.6 The appeal of
tDCS is its ease of application, cost, and ability to be deployed in a range of wide envi-
ronments7 (eg in- and out-patient clinics, mobile/field medical units, etc.).
Importantly, in numerous controlled clinical trials, tDCS has been shown to be ef-
fective in reducing clinical features of the aforementioned conditions that are refractory
to other treatments8 (eg pharmacological agents, physical, and/or cognitive therapy,
etc.). However, because clinical trials are inherently restricted in scope, time, and geog-
raphy, patient access to therapy in trials is often impractical ordifficult.Though there are
ongoing efforts to establish rigorous methods for remotely supervised clinical trials.9
For patients that have completed clinical trials, options for continuity of clinical care are
at best limited (if not wholly unavailable), even if patients have proven to be highly re-
sponsive. In light of this, patientswhomay gain clinical benefit from tDCS treatment of-
ten are unable to access clinical venues for its safe and apt provision, increasing the bur-
den of disease. If denied access to provision to tDCS undermedical care, some patients
will then seek alternative resources. One such avenue is the growing body of informa-
tion available via the internet regarding ‘do-it-yourself’ (DIY) approaches, which may
include adaptation of commercially available devices (eg iontophoresis) for transcra-
nial neuromodulation.10 Furthermore, the issues addressed here are not related to the
ethico-legal concerns generated byDIY or direct-to-consumer tDCS,11 but rather refer
to consequences of denying patients supervised, well-controlled tDCS clinical care.
In sum, when considering the possible use of tDCS, it becomes important to ad-
dress potential harms of both omission and commission. In the former instance, there
is defined risk of incurring increased burden of illness by not engaging tDCS to treat pa-
tients in whom other interventions have been shown to be ineffective, impractical, or
to produce deleterious effects. In the latter, there is theoretical risk of eliciting adverse
effects by employing tDCS. We posit that more finely grained assessment of extant in-
formation available about tDCS effects and effectiveness under specific conditions and
when treating particular types of patients will be essential to establish a more balanced
6 John R. Shook, Lucia Galvagni & James Giordano, Cognitive Enhancement Kept Within Contexts: Neuroethics
and Informed Public Policy, 8 FRONT. SYST. NEUROSCI. 228 (2014); Jay Gill, Priyanka P. Shah-Basak & Roy
Hamilton, It’s the Thought That Counts: Examining the Task-dependent Effects of Transcranial Direct Current
Stimulation on Executive Function, 8 BRAIN STIMUL. 253–59 (2015).
7 Jared Cooney Horvath, Jason D. Forte & Olivia Carter, Evidence that Transcranial Direct Current Stimulation
(tDCS) Generates Little-to-no Reliable Neurophysiologic Effect Beyond MEP Amplitude Modulation in Healthy
Human Subjects: A Systematic Review, 66 NEUROPSYCHOLOGIA 213–36 (2015).
8 Marine Mondino et al., Transcranial Direct Current Stimulation for the Treatment of Refractory Symptoms of
Schizophrenia. Current Evidence and Future Directions, 21 CURR. PHARM. DES. 3373–83 (2015).
9 Leigh E. Charvet et al., Remotely-Supervised Transcranial Direct Current Stimulation (tDCS)
for Clinical Trials: Guidelines for Technology and Protocols, 9 FRONT. SYST. NEUROSCI. (2015),
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362220/ (accessed Nov 10, 2015); Margaret Kass-
chau et al.,Transcranial Direct Current Stimulation is Feasible for Remotely Supervised Home Delivery in Multiple
Sclerosis, NEUROMODULATION (2016).
10 Anna Wexler, A Pragmatic Analysis of the Regulation of Consumer Transcranial Direct Current Stimulation
(tDCS) Devices in the United States, 2 J. L. BIOSCI. 669–96 (2016).
11 Marom Bikson, Sven Bestmann & Dylan Edwards, Neuroscience: Transcranial Devices are not Playthings, 501
NATURE 167–67 (2013); Nicholas S. Fitz & Peter B. Reiner,The Challenge of Crafting Policy for do-it-Yourself
Brain Stimulation, J.MED.ETHICS 101458 (2013);AnnaWexler,ThePractices of do-it-Yourself Brain Stimulation:
Implications for Ethical Considerations and Regulatory Proposals, 42 J. MED. ETHICS 102704 211 (2015).
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stance toward use and non-use, and in this way ameliorate the possibility of both types
of harm.
Pursuant to this goal, and with patient care ascendant, we advocate (1) that those
tDCS protocols under systematic testing in clinical trials be made available, under lim-
ited conditions, in clinical care; (2) that guidelines and regulations for clinical use be
focused upon and reflective of realistic assessment of all extant information available
to date; (3) ongoing research—under ecologically valid, clinical conditions—be sus-
tained and expanded to inform ongoing care decisions; so as to contribute to (4) de-
veloping an iterative, accurate and usable repository of data derived from laboratory
studies and practice experiences to guide the safe and sound use of tDCS in defined
clinical contexts12.
Toward these ends, regulatory oversight will be both important and required, as this
is an established protocol for both drug- and device-based interventions to be used to
effect medical benefit. Pharmacological compounds are strategically validated by the
producing commercial entity, and industry-sponsored research entails formulaic pre-
clinical and clinical phases, pursuant to FDA review and ultimate approval. Yet, it is
noteworthy that in theUnited States, a number of compounds are employed ‘off-label’.
In its general form, tDCS is not a proprietary technique; tDCS research is ‘investiga-
tor initiated’ and thus the extant corpus of completed tDCS studies—many of which
appear to demonstrate positive therapeutic outcomes—are heterogeneouswith regard
to dose, patient selection/inclusion, adjunct treatment(s) and outcome metrics. One
salient finding gained from review of these studies is that tDCS effects are relatively
selective and specific, as dependent upon context of the intervention and certain neu-
rocognitive characteristics of the subjects involved.13 The diversity of these contexts
can render it difficult for practitioners to easily and accurately assess both particular
effectiveness, and broad clinical benefit with respect to defining patient selection, and
treatment parameters. But the development and validationof tDCS is distinct from that
conventional proprietary drugs, and so the diversity of tDCS clinical-trial designs (and
so outcomes) should be understood to reflect a broad investigator-initiated (and typi-
cally government and foundation funded) effort.
At present, tDCS trials are reviewed and conducted in accordance with the ‘Non-
Significant-Risk’ designation for medical devices.14 Typical side effects of tDCS are
temporary skin irritation and itching at the sites of electrode placement, with the in-
cidence of other common side effects comparable to sham.15 It is important to note
that, in controlled human trials, no serious adverse effects (ADEs) of tDCS treatment
12 Lauren Treene, AnnaWexler & James Giordano, TOWARD AN INTEGRATIVE DATABASE OF/FOR TRANSCRANIAL
ELECTRICAL STIMULATION: DEFINING NEED, AND POSITING APPROACHES, BENEFITS AND CAVEATS (2015),
http://www.neuroethicssociety.org/2015-annual-meeting-abstracts (accessed August 30, 2016).
13 Beatrix Krause & Roi Cohen Kadosh, Not all Brains are Created Equal: The Relevance of Individual
Differences in Responsiveness to Transcranial Electrical Stimulation, 8 FRONT. SYST. NEUROSCI. (2014),
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932631/ (accessed May 6, 2016); Gill, Shah-Basak &
Hamilton, supra note 6.
14 F Fregni et al., Regulatory Considerations for the Clinical and Research Use of Transcranial Direct Current Stimu-
lation (tDCS): Review and Recommendations from an Expert Panel, 32 CLIN. RES. REGUL. AFF. 22–35 (2015).
15 Bhaskar Paneri et al., Tolerability of Repeated Application of Transcranial Electrical Stimulation with
Limited Outputs to Healthy Subjects, 9 BRAIN STIMUL. BASIC TRANSL. CLIN. RES. NEUROMODULATION
740–754 (2016), http://www.brainstimjrnl.com/article/S1935-861X(16)30104-8/references (accessed
August 30, 2016).
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have been reported after greater than 50,000 sessions of tDCS in diverse patient pop-
ulations at numerous institutions.16 The risk of tDCS is considered to be so low that
routine testing is acceptable in healthy volunteers.17 Indeed, such considerations are
of equal merit when addressing and assessing relative benefits and risks of employing
tDCS to treat patients suffering from severe neuropsychiatric disorders.
The official regulatory posture governing the use of tDCS is progressive,18 with cur-
rent regulation in theEUsupporting the use of tDCS in the treatment of depression and
pain. In most cases, the use of tDCS remains investigational or off-label therapy. In the
United States, the prescribed use(s) of investigational devices remain highly regulated
in compliance with FDA Quality Systems and/or IEC certification standards. When
medical devices are used with the intent to treat (outside of the context of a clinical
trial), FDA approval is not necessarily required.19 However,Wexler et al., 201520 notes
that laws regarding consumer safety and advertising still apply to thesemedical devices
when used outside of clinical trials.We agreewithWexler et al. that clinicians currently,
and could continue to repurpose iontophoresis devices for ‘off-label’ tDCS treatments,
as such practice is legal in the United States. However, this does not, nor should not
suggest cavalier use of tDCS in clinical contexts. A framework of ethical responsibili-
ties, inquiry, and considerations important to the use of any neurotechnology has been
proposed, and we advocate that this should be taken into account prior to engaging
tDCS in research and practice.21 Guidance documents on best practices continue to be
updated22 andpractitioner certification available.23 Onlymedical-gradedevices and ac-
cessories provide adequate assurance of reliability and reproducibility in the context of
clinical care.
Physicians remain obligated to obtain and employ the most current knowledge
about the product (including if it is manufactured to medical device standards),
and subject-specific dose and treatment profiles.24 Such knowledge should be based
upon both scientific rationale and sound medical evidence (eg clinical trials, reports
of investigator-initiated research, empirical laboratory studies relevant to the focus
and scope of intended use-in-practice, and evidence-based reviews), and in this light,
there is an equally strong imperative to stringently maintain medical records of use,
16 Andre Russowsky Brunoni et al., A Systematic Review on Reporting and Assessment of Adverse Effects Associated
with Transcranial Direct Current Stimulation, 14 INT. J. NEUROPSYCHOPHARMACOL. 1133–45 (2011).
17 Brian A. Coffman, Vincent P. Clark & Raja Parasuraman, Battery Powered Thought: Enhancement of Attention,
Learning, and Memory in Healthy Adults using Transcranial Direct Current Stimulation, 85 NEUROIMAGE 895–
908 (2014).
18 Fregni et al., supra note 13.
19 Office of the Commissioner, SEARCH FOR FDA GUIDANCE DOCUMENTS-, http://www.fda.gov/
RegulatoryInformation/Guidances/ucm126486.htm (accessed Apr. 27, 2016).
20 Wexler, supra note 9.
21 James Giordano, Conditions for Consent to the Use of Neurotechnology: A Preparatory Neuroethical Approach to
Risk Assessment and Reduction, 6 AJOBNEUROSCI. 12–14 (2015); JamesGiordano,A Preparatory Neuroethical
Approach to Assessing Developments in Neurotechnology, 17 VIRTUALMENTOR 56–61 (2015).
22 Alexandre F. DaSilva et al., Electrode Positioning and Montage in Transcranial Direct Current Stimulation, J. VIS.
EXP. (2011), http://www.jove.com/index/Details.stp?ID=2744 (accessed May 24, 2016); A. J. Woods et al.,
ATechnical Guide to tDCS, and Related Non-Invasive Brain Stimulation Tools, 127CLIN.NEUROPHYSIOL. 1031–
48 (2016).
23 NYC tDCS Fellowship 2016, http://neuromodec.com/event/nyc-tdcs-fellowship-2016/ (accessed May 24,
2016).
24 Giordano, supra note 19.
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therapeutic outcomes and any and all side effects, so as to contribute to the body infor-
mation available to guide current and future use.25 Patients should be fully informed
of known effects, effectiveness, and limitations, so as to insure probity of consent. And
continued clinical care should bemade available and accessible to patients should treat-
ment be ineffective or elicit any side effects that would require mitigative intervention
even if there are no established hazards.26
In conclusion, we argue that the information about the efficacy, effectiveness and
safety of tDCS available to date defensibly supports our position that:
 tDCS is broadly considered safe for routine application even in healthy subjects, and
investigator-initiated controlled clinical trials have suggested effectiveness in reduc-
ing particular symptoms of defined neuropsychiatric disorders/conditions.
 To withhold treatment of patients in acute need, pending resolution of all mecha-
nistic questions, completion of pivotal trials that exactly overlap the subject disease
etiology, and/or explicit approval from regulatory agencies will effectively prohibit
a majority of patients from the possibility of a demonstrably safe, and potentially
beneficial treatment.
 The study of tDCS should continue in order to develop and fortify the database of
information regarding the potential viability, utility, and value of this treatment, in
the spirit and tenor of responsibility to/of clinical equipoise.
 Any and all such research and clinical interventions should be conducted under the
purview and auspices of an ethically sound framework of preparation, review and
execution. tDCS interventions should only be applied in accordance with best prac-
tices and published guidelines in regards to both equipment and practitioner train-
ing.
 The off-label use of tDCS does not and should not in any way reduce manufacturers’
responsibility to meet medical device design guidelines, or physicians’ adherence to
technically apt and ethically sound treatment practices.
25 Treene, Wexler & Giordano, supra note 11.
26 Giordano, supra note 19.
